Molecular targets for treating cognitive dysfunction in schizophrenia.
about
Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health TreatmentDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersCNTRICS imaging biomarkers selection: Working memoryInsights into rapid modulation of neuroplasticity by brain estrogensSchizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition.Animal models of schizophrenia.Cognitive control deficits in schizophrenia: mechanisms and meaningThe evolution of drug development in schizophrenia: past issues and future opportunities.Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory.Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?Prefrontal activation deficits during episodic memory in schizophreniaQuantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophreniaExpression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disordersDevelopmental changes in human dopamine neurotransmission: cortical receptors and terminators.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions.Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Epigenetic signaling in schizophreniaReduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary studyComparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder.Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling.Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update.Rapid modulation of synaptogenesis and spinogenesis by 17β-estradiol in primary cortical neurons.Toxic effect of khat (Catha edulis) on memory: Systematic review and meta-analysis.Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugsFrontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia.Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in miceCognitive deficits in schizophrenia: short-term and long-term.Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaA randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.Perisomatic GABA release and thalamocortical integration onto neocortical excitatory cells are regulated by neuromodulators.Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophreniaInsights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases.Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.Group II metabotropic glutamate receptors and schizophrenia.
P2860
Q21129280-EF287782-CBB7-43AF-8DD8-0D065E0E884CQ26741515-654B9B39-DEA4-4A5B-8350-CA42C83EBE2CQ26748728-06B96512-1ABE-4F07-92A7-723B3067665AQ26852913-A3AF1D6B-2443-4D47-BBCB-E7DA452546E1Q26863428-DE9AD792-F161-4454-8815-4FCC690DD0B8Q28391148-252BC2D1-D917-4591-8CC4-C8826BB3999DQ30462828-4072A177-7462-4BFC-9471-9710E0BA040CQ30476447-E7411D9E-6252-45D1-8AD5-863527B28E0BQ30487850-9815E6B9-5C54-4FB0-9BAB-3AC52B732580Q30524657-F3588166-5F31-4C32-A04B-DC50A5BCC502Q30536299-C938E8D7-3956-45BF-A897-53BD0DF3CA5DQ33438218-69116BEA-A9D8-43D4-A817-978532FAE776Q33583171-1E4D9C0D-3252-4AA9-8826-3D8CA1D84B17Q33620592-FC1D6496-F5DE-4910-95F5-CF8F323B2448Q33846961-2D184D50-1FDA-4B1D-8F47-958147D3A4C6Q34050607-0CA1FD70-062D-4181-853F-19F409219B3FQ34159645-6C0767F6-8E98-49F2-8894-43D5682DDB98Q34274859-934723A0-2E77-4CF7-ACFE-300D9798E273Q34279073-ADE5C7FC-038A-4727-9E43-F7E475462AEBQ34381557-5AB9D66E-ECA7-4D5B-8125-46535B80E703Q34405264-FA7C533D-CE04-41A8-A73C-C3F84E5AE4C6Q34482708-6D38768A-5809-4CB3-90AA-B75A99AB9593Q34550685-000A13B3-CEA4-4920-A986-FBA57B0122FFQ34783324-D25A19FB-120D-4F7C-95C5-61B547B410FEQ35011307-7F3CDE57-B42D-43C2-A86E-2E508B1B7F85Q35176755-C39C6824-8D51-417D-9AA1-AE0099815096Q35407526-B2EB27B9-0DAE-4452-8F06-3655FB817F93Q36266902-ACE7721A-C70C-4C9E-B31F-DDC1711E5444Q36493481-4A618FC2-7E46-45CD-A1C1-9CBB5A7D9E99Q36540578-569FD15C-EE97-498B-AD11-73A7250B7B6DQ36555130-75B9D284-C8FB-40A1-8B66-289E132E3DE5Q36575378-1CB5E7D4-BE15-4473-8A45-B4BF528FDD92Q36579938-815B8FEB-2642-434B-BDBE-2C1B49074847Q36775219-FE724EA5-4F23-42FC-87DA-C326C35D5EBBQ36948049-0B4014F5-2C03-4095-9B4C-E159D5974327Q37041949-6EC1D204-1342-4DF7-8C7E-D7873BF9B6ECQ37068810-51BEBD25-0990-4356-A98A-69FFB7EF9156Q37183932-9D588667-C2B2-400B-9A41-62F05D40194BQ37358657-4ABDF8A5-0454-43DC-9228-96CF81515607Q37473779-81C8062B-D1A0-4F1E-88E6-D6A54373DED1
P2860
Molecular targets for treating cognitive dysfunction in schizophrenia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Molecular targets for treating cognitive dysfunction in schizophrenia.
@ast
Molecular targets for treating cognitive dysfunction in schizophrenia.
@en
type
label
Molecular targets for treating cognitive dysfunction in schizophrenia.
@ast
Molecular targets for treating cognitive dysfunction in schizophrenia.
@en
prefLabel
Molecular targets for treating cognitive dysfunction in schizophrenia.
@ast
Molecular targets for treating cognitive dysfunction in schizophrenia.
@en
P2860
P356
P1476
Molecular targets for treating cognitive dysfunction in schizophrenia
@en
P2093
Bryan L Roth
P2860
P304
P356
10.1093/SCHBUL/SBM074
P407
P50
P577
2007-07-07T00:00:00Z